{"id":"abp-938","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Atypical femoral fractures"}]},"_chembl":{"chemblId":"CHEMBL5761691","moleculeType":null,"molecularWeight":"539.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABP 938 targets RANKL (receptor activator of nuclear factor kappa-B ligand), a key mediator of osteoclast differentiation and activation. By inhibiting RANKL signaling, the drug reduces bone resorption and is being developed for conditions characterized by excessive bone loss. This mechanism is similar to denosumab, an established monoclonal antibody against RANKL.","oneSentence":"ABP 938 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:40.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Bone loss in patients with hormone-sensitive prostate cancer receiving androgen deprivation therapy"}]},"trialDetails":[{"nctId":"NCT04270747","phase":"PHASE3","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-06-22","conditions":"Neovascular (Wet) Age-related Macular Degeneration (AMD)","enrollment":576},{"nctId":"NCT05704725","phase":"PHASE3","title":"A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-01-23","conditions":"Chorioretinal Vascular Disease","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PAVBLU™"],"phase":"phase_3","status":"active","brandName":"ABP 938","genericName":"ABP 938","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABP 938 is a RANKL inhibitor that blocks osteoclast activation and bone resorption. Used for Osteoporosis in postmenopausal women, Bone loss in patients with hormone-sensitive prostate cancer receiving androgen deprivation therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}